Read news on % response rate with our app.
Read more in the app
Zidesamtinib demonstrates 94% response rate in TKI-naive patients with advanced ROS1-positive NSCLC
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds - EurekAlert!
